Literature DB >> 2578609

Delay in the fetal globin switch in infants of diabetic mothers.

S P Perrine, M F Greene, D V Faller.   

Abstract

In the normal fetus, a switch from production of hemoglobin F (alpha 2 gamma 2) to hemoglobin A (alpha 2 beta 2) occurs at 28 to 34 weeks of gestation. In the fetus with beta-hemoglobinopathy or beta-thalassemia, this switch proceeds despite the morbidity that results when production of beta-globin is abnormal or reduced. Since insulin has recently been shown to induce renewed expression of some inactive genes, we studied globin biosynthesis during the natural evolution of the fetal globin switch under conditions of hyperinsulinemia, which occurs in infants of diabetic mothers. Such infants develop in a hyperglycemic environment, which produces reactive hyperinsulinemia. The normal increase in beta-globin production from pre-switch levels did not occur in 9 of 10 such infants at term, as compared with 11 normal infants, in whom the switch occurred by 36 to 39 weeks of gestation (P less than 0.0001). The delay in the switch from gamma-globin to beta-globin in this unique clinical setting may allow identification of physiologic factors that can modulate developmental gene suppression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578609     DOI: 10.1056/NEJM198502073120602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

Review 1.  Future prospects for treatment of hemoglobinopathies.

Authors:  J A Stamatoyannopoulos
Journal:  West J Med       Date:  1992-12

2.  Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.

Authors:  Yankai Zhang; Alireza Paikari; Pavel Sumazin; Carly C Ginter Summarell; Jacy R Crosby; Eric Boerwinkle; Mitchell J Weiss; Vivien A Sheehan
Journal:  Blood       Date:  2018-06-08       Impact factor: 22.113

3.  Induction of fetal hemoglobin by propionic and butyric acid derivatives: correlations between chemical structure and potency of Hb F induction.

Authors:  Effie Liakopoulou; Qiliang Li; George Stamatoyannopoulos
Journal:  Blood Cells Mol Dis       Date:  2002 Jul-Aug       Impact factor: 3.039

4.  Fetal hemoglobin silencing in humans.

Authors:  Patricia A Oneal; Nicole M Gantt; Joseph D Schwartz; Natarajan V Bhanu; Y Terry Lee; John W Moroney; Christopher H Reed; Alan N Schechter; Naomi L C Luban; Jeffery L Miller
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

5.  The switch from fetal to adult hemoglobin.

Authors:  Vijay G Sankaran; Stuart H Orkin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

Review 6.  Fetal haemoglobin induction in sickle cell disease.

Authors:  Alireza Paikari; Vivien A Sheehan
Journal:  Br J Haematol       Date:  2017-11-16       Impact factor: 6.998

7.  Fetal haemoglobin levels in adult type 1 (insulin-dependent) diabetic patients.

Authors:  P Diem; P Mullis; A Hirt; J J Schuler; W Bürgi; K A Zuppinger; A Teuscher
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

Review 8.  Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.

Authors:  S P Perrine; D V Faller
Journal:  Experientia       Date:  1993-02-15

9.  A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease.

Authors:  Zhenning He; J Eric Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

10.  Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells.

Authors:  Himanshu Bhatia; Jennifer L Hallock; Amrita Dutta; Shay Karkashon; Lauren S Sterner; Toru Miyazaki; Ann Dean; Jane A Little
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.